Shopping Cart
Remove All
Your shopping cart is currently empty
N-Acetyl-Ser-Asp-Lys-Pro
Copy Product Info
😃Good
Catalog No. TP1828Cas No. 127103-11-1
Acetyl Ser-Asp-Lys-Pro is formed in bone marrow cells by enzymatic processing of thymosin β4. It inhibits the entry of pluripotent hemopoietic stem cells into S-phase of the cell cycle and protects against Ara-C lethality in mice.
N-Acetyl-Ser-Asp-Lys-Pro
Copy Product Info😃Good
Purity: 99.85%
Catalog No. TP1828Cas No. 127103-11-1
Acetyl Ser-Asp-Lys-Pro is formed in bone marrow cells by enzymatic processing of thymosin β4. It inhibits the entry of pluripotent hemopoietic stem cells into S-phase of the cell cycle and protects against Ara-C lethality in mice.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $61 | In Stock | In Stock | |
| 10 mg | $103 | In Stock | In Stock | |
| 25 mg | $213 | In Stock | In Stock | |
| 50 mg | $321 | In Stock | In Stock | |
| 100 mg | $463 | In Stock | In Stock | |
| 200 mg | $652 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.85%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Acetyl Ser-Asp-Lys-Pro is formed in bone marrow cells by enzymatic processing of thymosin β4. It inhibits the entry of pluripotent hemopoietic stem cells into S-phase of the cell cycle and protects against Ara-C lethality in mice. |
| In vitro | N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP) is a specific substrate for the N-terminal site of ACE and increases five-fold during ACE inhibitor therapy. AcSDKP inhibited the proliferation of isolated cardiac fibroblasts (P<0.05) but significantly stimulated the proliferation of vascular smooth muscle cells. Flow cytometry of rat cardiac fibroblasts treated with AcSDKP showed significant inhibition of cell progression from G0/G1 phase to S phase. In cardiac fibroblasts transfected with a Smad-sensitive luciferase reporter construct, AcSDKP decreased luciferase activity by 55±9.7% (P=0.01). Additionally, AcSDKP decreased phosphorylation and nuclear translocation of Smad2 in cardiac fibroblasts. In conclusion, AcSDKP inhibits the growth of cardiac fibroblasts and TGFbeta1-stimulated phosphorylation of Smad2. Because AcSDKP increases substantially during ACE inhibitor therapy, this suggests a novel pathway independent of angiotensin II by which ACE inhibitors can inhibit cardiac fibrosis. |
| Molecular Weight | 487.5 |
| Formula | C20H33N5O9 |
| Cas No. | 127103-11-1 |
| Smiles | C([C@@H](NC([C@H](NC([C@@H](NC(C)=O)CO)=O)CC(O)=O)=O)CCCCN)(=O)N1[C@H](C(O)=O)CCC1 |
| Relative Density. | 1.382 g/cm3 at 20℃ (Predicted) |
| Sequence | Ac-Ser-Asp-Lys-Pro |
| Sequence Short | SDKP |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 10 mM, Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy N-Acetyl-Ser-Asp-Lys-Pro | purchase N-Acetyl-Ser-Asp-Lys-Pro | N-Acetyl-Ser-Asp-Lys-Pro cost | order N-Acetyl-Ser-Asp-Lys-Pro | N-Acetyl-Ser-Asp-Lys-Pro chemical structure | N-Acetyl-Ser-Asp-Lys-Pro in vitro | N-Acetyl-Ser-Asp-Lys-Pro formula | N-Acetyl-Ser-Asp-Lys-Pro molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.